From GlobeNewswire: 2024-07-08 17:00:00

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) has announced plans to offer and sell shares of its common stock, or pre-funded warrants, subject to market conditions. The Company intends to use the net proceeds for working capital, including preparing a new drug application for its Tonmya™ product candidate for fibromyalgia, and paying existing debt. The offering will be made through an effective shelf registration statement with the SEC. Dawson James Securities, Inc. is the sole placement agent for the offering. Interested parties should review all documents before investing to understand the terms and conditions.

Tonix is a biopharmaceutical company focused on CNS disorders, with a priority on submitting an NDA to the FDA in late 2024 for Tonmya1. Other products in development include TNX-102 SL for acute stress reaction and fibromyalgia-type Long COVID, as well as TNX-1300 for treating cocaine intoxication. The company’s immunology portfolio includes TNX-1500 targeting organ transplant rejection and autoimmunity. Tonix has commercial products like Zembrace® SymTouch® and Tosymra® for acute migraine. All product development candidates are investigational. More information can be found at www.tonixpharma.com.



Read more at GlobeNewswire: Tonix Pharmaceuticals Announces Proposed Public Offering